CYCF1-2 Antibody

What is CYFIP1/2 and what cellular functions does it regulate?

CYFIP1/2 belongs to the CYFIP family and plays multiple critical roles in cellular function. It serves as a component of the CYFIP1-EIF4E-FMR1 complex, where it functions as an adapter between EIF4E and FMR1, binding to the mRNA cap and mediating translational repression . Beyond translation regulation, CYFIP1/2 also regulates cytoskeletal dynamics by influencing the formation of membrane ruffles and lamellipodia . In neuronal cells, it plays a significant role in axon outgrowth .

At the molecular level, CYFIP1/2 binds to F-actin but not to RNA and forms part of the WAVE complex that regulates actin filament reorganization through interaction with the Arp2/3 complex . This actin remodeling activity is regulated by RAC1 . Additionally, CYFIP1/2 functions as a regulator of epithelial morphogenesis and may act as an invasion suppressor in certain cancers .

What applications can CYFIP1/2 antibodies be used for in research?

CYFIP1/2 antibodies demonstrate versatility across multiple experimental applications critical for molecular and cellular research:

For optimal results, it is recommended to titrate the antibody concentration in each specific experimental system . The antibody has demonstrated reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species .

What is the difference between CYFIP1 and CYFIP2, and does antibody selection matter?

While CYFIP1 and CYFIP2 share structural similarities and both interact with FMR1 protein, they have distinct functions in cellular contexts. Antibodies may target one specific protein or both, depending on their design. For example, the ab204129 antibody recognizes both CYFIP1 and CYFIP2 (noted as "Anti-CYFIP2 + CYFIP1 antibody") , while other antibodies may have specificity for one isoform.

What sample preparation methods are recommended for CYFIP1/2 detection in brain tissue?

For optimal detection of CYFIP1/2 in brain tissue samples, several preparatory considerations are important:

For immunohistochemistry (IHC) applications with CYFIP1/2 antibodies on brain tissue, antigen retrieval is crucial. The recommended approach is to use TE buffer at pH 9.0, though citrate buffer at pH 6.0 represents an alternative method . This retrieval step is particularly important for formalin-fixed, paraffin-embedded tissues where protein epitopes may be masked.

For Western blot applications, brain tissues should be homogenized in an appropriate lysis buffer containing protease inhibitors to prevent protein degradation. When working with CYFIP1/2, it's important to note the expected molecular weight: while the calculated molecular weight is 148 kDa, the observed molecular weight on gels is typically around 130 kDa . This discrepancy should be considered when interpreting results.

For immunoprecipitation from brain tissue, 0.5-4.0 μg of antibody is recommended for 1.0-3.0 mg of total protein lysate . This approach has been validated specifically in mouse brain tissue, making it a reliable starting point for researchers working with murine models.

How can CYFIP1/2 antibodies be validated for specificity in neuronal studies?

Validating CYFIP1/2 antibodies for neuronal studies requires a multi-faceted approach to ensure specificity and reliability:

First, researchers should perform Western blot analysis using positive controls known to express CYFIP1/2, such as human, mouse, or rat brain tissue . The antibody should detect a band at approximately 130 kDa, despite the calculated molecular weight being 148 kDa . This discrepancy is common with CYFIP1/2 and represents a validation checkpoint.

Second, knockout or knockdown validation is crucial. Comparing antibody signals in wild-type samples versus those with CYFIP1/2 genetically depleted provides definitive evidence of specificity. For antibodies claiming to recognize both CYFIP1 and CYFIP2 (like ab204129), validation should ideally include single and double knockout controls to confirm reactivity with both proteins .

Third, cross-reactivity testing should be performed by examining tissues known to express varying levels of CYFIP1/2. The antibody's pattern of reactivity should match known expression patterns of the target protein. For CYFIP1/2, brain tissue serves as a positive control, while expression may be lower in other tissues .

Finally, immunoprecipitation followed by mass spectrometry can provide additional validation by confirming that the antibody pulls down CYFIP1/2 and its known interaction partners, such as components of the WAVE complex or FMR1-related proteins .

What are the critical considerations when studying CYFIP1/2 in neurodevelopmental disorders?

When investigating CYFIP1/2 in neurodevelopmental disorders, researchers must address several methodological and interpretative challenges:

First, CYFIP1/2's role in the CYFIP1-EIF4E-FMR1 complex is particularly relevant as it mediates translational repression and promotes FMR1's translation repression activity in the brain . This connection to FMR1 (mutations in which cause Fragile X syndrome) makes CYFIP1/2 antibodies valuable tools for studying translational dysregulation in neurodevelopmental conditions. Researchers should design experiments that examine both protein expression levels and potential alterations in protein-protein interactions.

Second, given CYFIP1/2's role in axon outgrowth and actin dynamics , studies should incorporate morphological analyses of neuronal development alongside molecular investigations. This might include examining dendritic spine formation, axon extension, or growth cone dynamics in models of neurodevelopmental disorders using both imaging and biochemical approaches.

Third, researchers must carefully select appropriate model systems. While CYFIP1/2 antibodies have demonstrated reactivity in human, mouse, and rat samples , the specific isoform expression and function may vary across species and developmental stages. Time-course studies examining CYFIP1/2 expression during critical developmental windows are advised.

Finally, experimental designs should account for CYFIP1/2's interaction with RAC1 and the WAVE complex in regulating actin cytoskeleton reorganization . Disruptions to these interactions may contribute to neurodevelopmental phenotypes and should be examined using co-immunoprecipitation or proximity ligation assays alongside standard expression analyses.

How can CYFIP1/2 antibodies be optimized for dual immunofluorescence studies?

Optimizing CYFIP1/2 antibodies for dual immunofluorescence requires careful consideration of several technical parameters:

First, antibody compatibility must be addressed. When selecting a secondary antibody for CYFIP1/2 detection in dual staining, researchers should choose one that doesn't cross-react with the other primary antibody in use. For the rabbit polyclonal CYFIP1/2 antibody (16011-1-AP), compatible fluorophore-conjugated anti-rabbit secondary antibodies would be appropriate . In dual staining experiments, as demonstrated with ab204129, researchers have successfully used Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) alongside mouse antibodies detected with Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) .

Second, antigen retrieval conditions must be optimized. For CYFIP1/2 detection in tissues, TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 can be used as an alternative . When performing dual staining, it's critical to select a retrieval method compatible with both target antigens, which may require empirical testing.

Third, potential signal cross-contamination should be mitigated through sequential staining protocols. For instance, complete the staining protocol for one antigen before beginning the second, or use directly conjugated primary antibodies to avoid secondary antibody cross-reactivity.

Finally, proper controls must be implemented, including single-stained samples to establish bleed-through parameters and secondary-only controls to confirm specificity. For advanced applications, consider using spectral unmixing to separate closely overlapping fluorescent signals when studying CYFIP1/2 alongside other proteins in the same cellular compartments.

What approaches can resolve discrepancies between CYFIP1/2 antibody results in different experimental systems?

When researchers encounter conflicting results with CYFIP1/2 antibodies across different experimental systems, several systematic troubleshooting approaches can help resolve these discrepancies:

First, consider epitope accessibility variations. The CYFIP1/2 antibody 16011-1-AP targets a fusion protein immunogen (Ag8749) , while ab204129 is a recombinant monoclonal antibody . These different antibodies may recognize distinct epitopes that could be differentially accessible depending on sample preparation, fixation methods, or protein-protein interactions in various cellular contexts. Comparing results using multiple antibodies targeting different epitopes can help identify whether discrepancies are epitope-specific.

Second, evaluate post-translational modifications. CYFIP1/2 functions in diverse cellular processes, and its activity may be regulated by modifications that could mask antibody epitopes. If discrepancies appear between cell types or experimental conditions, phosphorylation-specific or modification-insensitive antibodies might help determine whether post-translational changes explain the variations.

Third, analyze protein complex formation. As CYFIP1/2 is part of the WAVE complex and interacts with the FMR1 complex , its detection may be impacted by complex formation. Native versus denaturing conditions in different experimental approaches (e.g., IHC versus Western blot) might yield different results based on whether the antibody's epitope is accessible in protein complexes.

Fourth, implement quantitative validation approaches. When discrepancies occur, researchers should quantitatively assess antibody performance across systems using standard curves with recombinant protein and direct comparison of detection methods. Absolute quantification techniques like mass spectrometry can serve as an antibody-independent validation method to resolve contradictory findings.

What controls are essential when using CYFIP1/2 antibodies in Western blotting?

Implementing proper controls for CYFIP1/2 antibody Western blotting is crucial for generating reliable and interpretable results:

Primary controls should include positive tissue samples known to express CYFIP1/2, such as human, mouse, or rat brain tissue, all of which have demonstrated positive Western blot detection with CYFIP1/2 antibodies . Researchers should expect to observe a band at approximately 130 kDa, which represents the observed molecular weight of CYFIP1/2 despite its calculated weight of 148 kDa .

Negative controls are equally important and should include samples known to have low or no expression of CYFIP1/2. Additionally, CYFIP1/2 knockdown or knockout samples provide the gold standard for negative controls, as they can definitively demonstrate antibody specificity. For antibodies that recognize both CYFIP1 and CYFIP2 (like ab204129), single and double knockouts can help distinguish between isoforms .

Loading controls must be carefully selected based on experimental design. Traditional housekeeping proteins like GAPDH or β-actin are appropriate for most applications, but researchers studying brain development or pathological conditions should verify that their chosen loading control remains stable across experimental conditions. For experiments examining CYFIP1/2's role in actin cytoskeleton regulation, selecting a loading control unrelated to actin dynamics would be prudent.

Finally, researchers should include antibody validation controls such as pre-adsorption tests or competing peptide controls when first implementing a new CYFIP1/2 antibody in their experimental system. This helps confirm that the detected signal truly represents the target protein.

How should researchers optimize CYFIP1/2 antibodies for immunohistochemistry in different tissue types?

Optimizing CYFIP1/2 antibodies for immunohistochemistry across tissue types requires systematic adjustment of key parameters:

First, antigen retrieval conditions must be tissue-specifically optimized. While TE buffer at pH 9.0 is generally recommended for CYFIP1/2 detection, with citrate buffer at pH 6.0 as an alternative , the optimal retrieval method may vary by tissue type. For brain tissue, where CYFIP1/2 has been successfully detected, the recommended conditions are well-established, but other tissues may require empirical testing of multiple retrieval buffers, pH conditions, and heating methods.

Second, antibody concentration should be adjusted according to tissue type and fixation method. The recommended dilution range for CYFIP1/2 antibody in IHC is 1:300-1:1200 , but researchers should perform titration experiments for each new tissue type. Begin with a dilution series spanning this range and evaluate signal-to-noise ratio to determine optimal concentration.

Third, incubation conditions need tissue-specific optimization. While standard protocols often recommend overnight incubation at 4°C, some tissues may benefit from different conditions. Dense tissues might require longer incubation times or the addition of penetration enhancers, while tissues with high endogenous biotin or peroxidase activity might need additional blocking steps.

The detection system should also be considered. While DAB-based chromogenic detection is common, tissues with high background may benefit from fluorescence-based detection, which offers greater sensitivity and the possibility of multi-labeling. For tissues where CYFIP1/2 expression is expected to be low, signal amplification systems like tyramide signal amplification may be beneficial.

What approaches can improve detection sensitivity when working with low CYFIP1/2 expression samples?

When studying samples with low CYFIP1/2 expression, several methodological approaches can enhance detection sensitivity:

For Western blotting applications, researchers should first optimize protein extraction methods to ensure maximum recovery of CYFIP1/2. Using specialized brain tissue lysis buffers may improve yield when working with neuronal samples. Increasing the amount of loaded protein (50-100 μg) while maintaining the recommended antibody dilution of 1:500-1:1000 can improve detection of low-abundance CYFIP1/2. Additionally, switching to more sensitive detection systems such as chemiluminescent substrates with enhanced formulations or fluorescent secondary antibodies can significantly lower detection thresholds.

For immunohistochemistry and immunofluorescence applications, signal amplification techniques are valuable. Tyramide signal amplification can increase sensitivity by 10-100 fold compared to conventional detection. When using CYFIP1/2 antibodies at the recommended dilution range of 1:300-1:1200 for IHC , adding a polymer-based detection system can further enhance signal without increasing background. Additionally, reducing section thickness to 3-5 μm can improve antibody penetration and signal intensity in tissue sections.

For flow cytometry applications, where CYFIP1/2 antibodies have been validated in Jurkat cells at 0.40 μg per 10^6 cells , sensitivity can be improved by optimizing fixation and permeabilization conditions to ensure optimal epitope accessibility while maintaining cellular integrity. Using fluorophores with higher quantum yields and implementing multi-laser excitation strategies can also enhance detection of low-level CYFIP1/2 expression.

For all applications, reducing background is as important as enhancing signal. Extended blocking steps with specialized blocking reagents containing both proteins and detergents can significantly improve signal-to-noise ratios when working with low-abundance targets like CYFIP1/2 in certain cell types or developmental stages.

How can CYFIP1/2 antibodies be utilized in studying its role in actin cytoskeleton regulation?

CYFIP1/2's involvement in actin cytoskeleton regulation through the WAVE complex can be effectively studied using specialized antibody-based approaches:

Co-immunoprecipitation (Co-IP) experiments represent a powerful approach to investigate CYFIP1/2's interactions with actin regulatory proteins. Using the CYFIP1/2 antibody at the recommended IP concentration (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) , researchers can pull down CYFIP1/2 along with its binding partners from the WAVE complex and analyze these interactions under different cellular conditions or stimuli. This technique has been validated specifically in mouse brain tissue , making it particularly relevant for neuronal studies.

Proximity ligation assays (PLA) offer an advanced method to visualize and quantify CYFIP1/2's interactions with actin regulatory proteins in situ. By combining CYFIP1/2 antibodies with antibodies against suspected interaction partners (such as WAVE complex components or RAC1), researchers can detect actual protein-protein interactions within cells with high sensitivity and specificity. This approach is especially valuable for studying dynamic interactions during processes like membrane ruffle formation or lamellipodia extension.

Live-cell imaging approaches can also incorporate CYFIP1/2 antibody fragments or nanobodies to track the dynamic localization of CYFIP1/2 in relation to actin structures. By combining this with fluorescently labeled actin and time-lapse microscopy, researchers can directly observe how CYFIP1/2 contributes to actin remodeling during cellular processes like migration or morphogenesis.

Finally, super-resolution microscopy techniques like STORM or PALM, when combined with CYFIP1/2 immunolabeling, can reveal the precise spatial organization of CYFIP1/2 in relation to actin filaments and other cytoskeletal components at nanometer resolution. This approach is particularly valuable for understanding how CYFIP1/2 structurally contributes to actin filament reorganization in processes such as axon outgrowth or synapse formation.

What are the potential causes and solutions for non-specific binding with CYFIP1/2 antibodies?

Non-specific binding with CYFIP1/2 antibodies can arise from several sources, each requiring specific troubleshooting approaches:

Cross-reactivity with related proteins represents a common source of non-specificity. The CYFIP family contains structurally similar proteins, and some antibodies like ab204129 are designed to recognize both CYFIP1 and CYFIP2 . When greater specificity is required, researchers should select antibodies raised against unique epitopes or validate results using genetic approaches like CYFIP1 or CYFIP2 knockout controls. Peptide competition assays can also help identify whether observed signals represent specific binding.

Suboptimal antibody concentration can contribute to non-specific binding. While recommended dilutions for CYFIP1/2 antibodies range from 1:500-1:1000 for Western blot and 1:300-1:1200 for IHC , each experimental system may require fine-tuning. Performing a dilution series experiment can help identify the optimal concentration that maximizes specific signal while minimizing background.

Fixation artifacts can also generate non-specific signals, particularly in immunohistochemistry. When working with CYFIP1/2 antibodies in fixed tissues, comparing different fixation methods (e.g., paraformaldehyde, methanol, or acetone) can help identify conditions that preserve epitope accessibility while reducing non-specific binding. For formalin-fixed tissues, optimizing antigen retrieval using the recommended TE buffer at pH 9.0 or alternative citrate buffer at pH 6.0 is essential.

How can researchers distinguish between CYFIP1 and CYFIP2 in experimental systems?

Distinguishing between CYFIP1 and CYFIP2 requires careful selection of approaches tailored to research requirements:

Isoform-specific antibodies represent the most straightforward approach when available. While some antibodies recognize both proteins (e.g., ab204129 is described as "Anti-CYFIP2 + CYFIP1 antibody") , others may have greater specificity for one isoform. Researchers should thoroughly review specificity data and validation studies when selecting antibodies for isoform-specific detection. Western blotting against recombinant CYFIP1 and CYFIP2 standards can help confirm an antibody's specificity profile.

Genetic manipulation approaches offer definitive isoform distinction. Using CYFIP1 or CYFIP2 knockout cell lines or tissues as controls can unambiguously identify which isoform is detected by a given antibody. Similarly, siRNA or shRNA knockdown of individual isoforms can help distinguish between them in Western blot or immunostaining applications.

Mass spectrometry following immunoprecipitation provides another powerful approach. By using a pan-CYFIP1/2 antibody for immunoprecipitation followed by mass spectrometry analysis, researchers can identify peptides unique to each isoform and quantify their relative abundance. This approach is particularly valuable for studying the composition of CYFIP-containing complexes across different cellular contexts.

RNA-level analysis can complement protein detection methods. RT-qPCR or RNA-seq using isoform-specific primers can quantify CYFIP1 versus CYFIP2 expression at the transcript level. When combined with protein-level measurements, this approach can provide insights into potential post-transcriptional regulation of CYFIP isoforms.

What considerations are important when selecting CYFIP1/2 antibodies for studying protein-protein interactions?

When investigating CYFIP1/2's interactions with binding partners such as components of the CYFIP1-EIF4E-FMR1 complex or the WAVE complex , antibody selection requires special considerations:

Epitope location is critically important as it may interfere with or be masked by protein-protein interactions. Antibodies targeting epitopes within interaction domains may disrupt native complexes or fail to recognize CYFIP1/2 when it's engaged with partners. Reviewing the immunogen information is essential – for example, antibody 16011-1-AP uses CYFIP1/2 fusion protein Ag8749 as its immunogen . Researchers should select antibodies with epitopes unlikely to be occluded in the protein complexes of interest, ideally validating multiple antibodies targeting different regions.

Antibody format considerations are also important. For co-immunoprecipitation studies, where CYFIP1/2 antibodies have been successfully used with mouse brain tissue , researchers should ensure the antibody binds effectively under the mild detergent conditions necessary to preserve protein-protein interactions. Native versus denatured protein recognition is another critical factor – some antibodies may only recognize denatured epitopes exposed in Western blotting but not accessible in native complexes.

Cross-reactivity potential must be evaluated, particularly when studying CYFIP1/2 interactions with related proteins. Antibodies should be pre-cleared against potential cross-reactive proteins or validated in systems where confounding proteins are absent. This is especially important when studying interactions within protein families with high homology.

Finally, functional impact assessment is crucial. Some antibodies may recognize their target but disrupt its function or interactions. For studying CYFIP1/2's role in processes like translation repression or actin remodeling, researchers should confirm that antibody binding doesn't alter the protein's functional properties, ideally through activity assays performed in the presence and absence of the antibody.

How can CYFIP1/2 antibodies be applied in studying neurodevelopmental and psychiatric disorders?

CYFIP1/2 antibodies offer valuable tools for investigating neurodevelopmental and psychiatric conditions, given the protein's roles in translational control and cytoskeletal regulation :

In post-mortem tissue studies, CYFIP1/2 antibodies can reveal expression pattern alterations associated with disorders. The validated applications in human brain tissue make these antibodies suitable for examining CYFIP1/2 levels and localization in samples from patients with conditions like autism spectrum disorders, schizophrenia, or intellectual disability. Researchers should apply the recommended IHC dilution (1:300-1:1200) while optimizing conditions for post-mortem tissues, which may require modified antigen retrieval protocols.

For functional studies in cellular models, CYFIP1/2 antibodies can help investigate disruptions in protein-protein interactions. Co-immunoprecipitation using the recommended antibody amounts (0.5-4.0 μg for 1.0-3.0 mg of total protein) can reveal whether disease-associated mutations or conditions alter CYFIP1/2's interactions with FMR1 or components of the WAVE complex, potentially affecting translational regulation or cytoskeletal dynamics.

In developmental analyses, CYFIP1/2 antibodies can track expression changes during critical neurodevelopmental windows. Combining immunohistochemistry with lineage markers can reveal cell type-specific alterations in CYFIP1/2 expression or localization in disease models. This approach is particularly valuable for understanding how CYFIP1/2 dysregulation might contribute to neurodevelopmental trajectory alterations associated with psychiatric conditions.

For genetic studies, CYFIP1/2 antibodies provide protein-level validation of genomic findings. When genomic studies identify CYFIP1/2 variants associated with neuropsychiatric conditions, antibody-based approaches can determine whether these variants affect protein expression, stability, localization, or interaction partners, thus bridging the gap between genetic association and functional consequences.